The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

Small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC) remain 2 of the most aggressive thoracic malignancies, marked by poor prognoses and limited treatment options. Recent ...

World Lung Cancer Day has been observed every year on August 1 since 2012 to raise awareness about the risk of the disease.

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the Main Board of The Stock Exchange of Hong ...

DLL3 is upregulated across multiple solid tumor types where significant unmet need remains, including SCLC, neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC) and melanoma.

The companies noted that a U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025. DLL3 is expressed in several tumor types including SCLC, neuroendocrine tumors, non ...

STUTTGART, Germany I August 04, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis.

SAN ANTONIO, July 23, 2025--CyPath® Lung detected a Stage 1A neuroendocrine tumor in a patient's lung when imaging and other adjuvant tools could not.

CyPath® Lung detected a Stage 1A neuroendocrine tumor in a patient's lung when imaging and other adjuvant tools could not.

Midkine is highly expressed in SCLC, correlating with tumor burden and potentially aiding in diagnosis and prognosis. The study found midkine activates the AKT pathway, but its connection to the ...